Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Addiction. 2013 Jun 7;108(10):1697–1699. doi: 10.1111/add.12243

AT THE CROSSROADS: HIV PREVENTION AND TREATMENT FOR PEOPLE WHO INJECT DRUGS IN UKRAINE

Martha J Bojko 1,2, Sergey Dvoryak 1, Frederick L Altice 1,2,3,4
PMCID: PMC3775865  NIHMSID: NIHMS482164  PMID: 23745777

By 2009, HIV incidence decreased globally by 19% while rates in Eastern Europe and Central Asia increased by 25%, primarily among people who inject drugs (PWIDs) (1). Regionally, Ukraine and Russia account for 90% of new HIV infections and while there is evidence that the HIV epidemic is transitioning to a generalized epidemic, Ukraine's volatile and expanding HIV epidemic is still being fueled by PWIDs, primarily using opioids (2). Among the ~375,000–425,000 PWIDs, HIV prevalence ranges from 21.3%–41.8% and PWIDS account for nearly 70% of all cumulative and 56% of new HIV infections (3, 4).

Medication-assisted therapies (MAT), especially methadone (MMT) and buprenorphine maintenance treatment (BMT), are internationally recognized as the most effective treatment for opioid dependence (5); newer data suggest extended-release naltrexone is also effective (6). MAT also remains among the most effective primary and secondary HIV prevention strategies available, especially when used as part of a “combination intervention” approach integrated with needle/syringe exchange programs (NSEPs), antiretroviral therapy (ART); peer education and outreach; expanded HIV testing; and contextual promotion of public policies and other structural changes conducive to promote public health (7). Within the region, Ukraine initially implemented relatively progressive, but insufficiently scaled-to-need, “combination interventions” promoting HIV prevention and treatment for PWIDs. Harm reduction programs including outreach and peer education, condom distribution, voluntary HIV testing, and NSEPs were started in Ukraine in the late 1990s, followed by ART expansion in 2004. Pilot opioid substitution therapy (OST) programs using BMT began that year (8); MMT commenced in 2008 (9). In 2008, international donors funded creation of integrated care services for PWIDs through pilot programs in Kyiv, Dnipropetrovsk, Mykolaiv and Odessa that simultaneously provided treatment for HIV, tuberculosis and OST (10).

Unlike nearby Russia where HIV prevention and treatment efforts for PWIDs are flailing and OST is legislatively banned (11), Ukraine has made progress, but is now at a crossroads. While MAT is highly effective in reducing HIV risk behaviors, increasing access to ART, and improving HIV treatment access, retention and other outcomes (5), less than 2% of PWIDs in Ukraine are currently receiving this critical therapy despite available, funded OST slots (12). It is unclear if this inertia is due to inadequate commitment or insufficient funding, but data suggest that recent Ukrainian efforts to expand MAT services for PWIDs have been hindered by multiple structural barriers including restricted access to services, human rights abuses, police harassment including arrest, detention and incarceration, and unsupportive policy or social environments (13, 14). For example, the Ukrainian Ministry of Health's 2012 order No. 200 (15), which newly requires PWIDs to provide documentation of two failed detoxification attempts before being admitted to OST, abrogates recent attempts to expand OST. Detoxification of chronically dependent PWIDs is associated with death, suffering and wasted time, energy, and resources for patients who would otherwise benefit from it (16). In addition, both OST clients and medical staff must adhere to the strict legal controls which regulate the distribution of methadone in Ukraine: any legal violations of the “About Narcotics Turnover” law is treated seriously and even technical errors made by medical staff can result in arrest and detention. Police also create additional difficulties for OST clients and threaten medical staff (14). As a result, most medical facilities fear establishing OST sites within their clinics (17).

These seemingly incipient negative trends in HIV policy and programming in Ukraine place at odds an evidence-based HIV policy foundation with new and emerging national laws, legislation, and policies now hindering responsiveness to policy and changing epidemic patterns. A 2011 HIV policy evaluation confirmed that at both the national and local levels, “implementation, coordination, and collaboration are often left to individual personalities and interests of those involved” and that many of the structural barriers to HIV program planning revolve around a lack of detailed operational guidelines or implementation plans, inadequate strategic planning, insufficient resources to implement laws and regulations, and a lack of awareness and acceptance of legal protections for vulnerable populations among key stakeholder groups, including law enforcement, local government, and healthcare providers (18).

In order to forge ahead on the earlier adopted progressive path and remain an innovative regional leader of HIV prevention and treatment for PWIDs, there is an urgent need for the Ukrainian government to redress the gaps and barriers in HIV policy and provision of prevention and treatment services for PWIDs. Ukraine's current OST program is heavily dependent on funding from the Global Fund to Fight AIDS, Tuberculosis, and Malaria (GFATM), due to expire in 2016, and the 2011 decision to cancel its next funding cycle due to insufficient funds potentially jeopardizes future OST services in Ukraine unless Ukraine's Ministry of Health opts to subsidize it. Without governmental financial support, HIV prevention and treatment will revert back to nihilist strategies extant in nearby Russia where HIV prevention and treatment efforts among PWIDs are inconsistent with evidence-based care and human rights mandates (11).

Expanding MAT for PWIDs and working with clients, providers and stakeholders to make these programs culturally relevant and logistically acceptable in the Ukrainian context is an opportunity to increase access to and retention in services while also raising community and stakeholder awareness of the societal and public health benefits of these evidence-based interventions. Mathematical modeling confirms MAT expansion as the most cost-effectiveness HIV prevention and treatment strategy in Ukraine's transitioning HIV epidemic and importantly, expanding MAT coverage to 25% of PWIDs along with ART coverage to 80% of HIV-infected persons who need it would avert 8,300 new HIV infections annually (3).

It is crucial that Ukraine treats drug dependence not as a crime but humanely as a chronic, relapsing disease similarly to any other chronic medical condition that affects individuals, regardless of age, socio-economic status, political affiliation, or sexual orientation and which requires consistent, evidence-based treatment options adapted to the Ukrainian cultural context and understood and accepted by all stakeholders. An HIV epidemic fueled by PWIDs is no longer “somebody else's problem.” The Ministry of Health's recent willingness to revisit Order No. 200 as well as the June 2012 submission to the Ukrainian government of a new national drug strategy prepared by the Ukrainian State Drug Control Committee and UNODC (19) are hopeful signs that Ukraine is moving forward. A progressive path remains the only solution for improving the health of the individual, the healthcare system and Ukrainian society. Anything less will set Ukraine on a downward trajectory that will reverse its many recent gains, including the secondary benefits to its neighbors who have similarly adopted evidence-based HIV prevention and treatment strategies that are consistent with public health and human rights.

Concise Statement.

Ukraine's regional leader role over a decade on HIV prevention and treatment for people who inject drugs (PWIDs) is now at a crossroads. Recent policy decisions and restrictive practices, however, are hindering access to and retention of PWIDs in evidence-based treatment programs. At this juncture, Ukraine must redress the gaps and barriers in HIV policy and service provision for PWIDs.

Acknowledgments

Funding: The authors would like to thank the National Institutes on Drug Abuse for funding for research (R01 DA029910 and R01 DA033679) and career development (K24 DA017072) as well as the Global Health Equity Scholars Program funded by the Fogarty International Center and the National Institute of Allergy and Infectious Diseases (Research Training Grant R25 TW009338).

REFERENCES

  • 1.UNAIDS . Global report: UNAIDS report on the global AIDS epidemic 2010. Geneva, Switzerland: 2010. [Google Scholar]
  • 2.Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375:1014–28. doi: 10.1016/S0140-6736(10)60232-2. [DOI] [PubMed] [Google Scholar]
  • 3.Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLoS Med. 2011;8:e1000423. doi: 10.1371/journal.pmed.1000423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Des Jarlais DC, Feelemyer JP, Modi SN, et al. Transitions from injection-drug-use-concentrated to self-sustaining heterosexual HIV epidemics: patterns in the international data. PLoS One. 2012;7:e31227. doi: 10.1371/journal.pone.0031227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376:59–79. doi: 10.1016/S0140-6736(10)60829-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377:1506–13. doi: 10.1016/S0140-6736(11)60358-9. [DOI] [PubMed] [Google Scholar]
  • 7.Degenhardt L, Mathers B, Vickerman P, et al. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376:285–301. doi: 10.1016/S0140-6736(10)60742-8. [DOI] [PubMed] [Google Scholar]
  • 8.Bruce RD, Dvoryak S, Sylla L, Altice FL. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications. Int J Drug Policy. 2007;18:326–8. doi: 10.1016/j.drugpo.2006.12.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Schaub M, Chtenguelov V, Subata E, Weiler G, Uchtenhagen A. Feasibility of buprenorphine and methadone maintenance programmes among users of home made opioids in Ukraine. Int J Drug Policy. 2010;21:229–33. doi: 10.1016/j.drugpo.2009.10.005. [DOI] [PubMed] [Google Scholar]
  • 10.Sylla L, Bruce RD, Kamarulzaman A, Altice FL. Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. Int J Drug Policy. 2007;18:306–12. doi: 10.1016/j.drugpo.2007.03.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.COHEN J. No opiate substitutes for the masses of IDUs. Science. 2010;329:165–7. doi: 10.1126/science.329.5988.165. [DOI] [PubMed] [Google Scholar]
  • 12.Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376:355–66. doi: 10.1016/S0140-6736(10)60832-X. [DOI] [PubMed] [Google Scholar]
  • 13.Jolley E, Rhodes T, Platt L, et al. HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with implications for policy. BMJ Open. 2012;2 doi: 10.1136/bmjopen-2012-001465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Mimiaga MJ, Safren SA, Dvoryak S, et al. “We fear the police, and the police fear us”: structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine. AIDS Care. 2010;22:1305–13. doi: 10.1080/09540121003758515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Ukraine Ministry Of Health [(accessed 14 April 2013)];Pro zatverdzennia Poriadku provedennia zamisnoji pidtrimuval'noji terapiji xvoryx z opiodnoju zalezhnistju. 2012 Available at: http://www.moz.gov.ua/ua/portal/dn_20120327_200.html.
  • 16.Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361:662–668. doi: 10.1016/S0140-6736(03)12600-1. [DOI] [PubMed] [Google Scholar]
  • 17.Cohen J. Law enforcement and drug treatment: a culture clash. Science. 2010;329:169. doi: 10.1126/science.329.5988.169. [DOI] [PubMed] [Google Scholar]
  • 18.Judice N, Zaglada O, Mbuya-Brown R. HIV Policy Assessment: Ukraine. Futures Group, Health Policy Project; Washington, D.C.: 2011. [Google Scholar]
  • 19.Ukrainian State Drug Control Committee [(accessed 23 April 2013)];Project National Drug Strategy of Ukraine for the period through 2020. 2013 Available at: http://narko.gov.ua/index.php/proekt-strategiji/288-proekt-natsionalnoji-strategiji-ukrajini-shchodo-narkotikiv-na-period-do-2020-roku.

RESOURCES